Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
15
ELTP Quote, Financials, Valuation and Earnings
Last price:
$0.38
Seasonality move
:
30.9%
Day range:
$0.39 - $0.41
52-week range:
$0.27 - $0.82
Dividend yield:
0%
P/E ratio:
18.03x
P/S ratio:
3.08x
P/B ratio:
5.25x
Volume:
511.8K
Avg. volume:
848.2K
1-year change:
-20.15%
Market cap:
$421.3M
Revenue:
$84M
EPS (TTM):
$0.02
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ELTP
Elite Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.95% | $31.80 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
GKOS
Glaukos Corp.
|
$137M | -$0.20 | 28.42% | -14.86% | $134.79 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
|
YCBD
cbdMD, Inc.
|
$4.9M | -- | 11.43% | -- | $2.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ELTP
Elite Pharmaceuticals, Inc.
|
$0.39 | -- | $421.3M | 18.03x | $0.00 | 0% | 3.08x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.81 | $31.80 | $3.9B | 9.97x | $0.00 | 0% | 3.61x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$325.07 | $457.00 | $43.1B | 144.02x | $0.00 | 0% | 11.68x |
|
GKOS
Glaukos Corp.
|
$121.12 | $134.79 | $7B | -- | $0.00 | 0% | 13.65x |
|
SVRA
Savara, Inc.
|
$6.01 | $10.81 | $1.2B | -- | $0.00 | 0% | -- |
|
YCBD
cbdMD, Inc.
|
$0.81 | $2.00 | $8.5M | -- | $0.00 | 0% | 0.26x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ELTP
Elite Pharmaceuticals, Inc.
|
7.01% | 3.643 | 1.15% | 5.38x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 3.124 | 1.15% | 3.40x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 0.880 | 5.64% | 2.51x |
|
GKOS
Glaukos Corp.
|
13.97% | 0.983 | 1.64% | 3.91x |
|
SVRA
Savara, Inc.
|
24.02% | -2.483 | 4.83% | 7.42x |
|
YCBD
cbdMD, Inc.
|
6.18% | 0.621 | 4.36% | 1.84x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ELTP
Elite Pharmaceuticals, Inc.
|
$12.6M | $9M | 67.69% | 77.64% | 28.53% | -$5.5M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
GKOS
Glaukos Corp.
|
$111.4M | -$27M | -22.09% | -25.22% | -18.87% | -$12.7M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
|
YCBD
cbdMD, Inc.
|
$2.8M | -$286.3K | -39.12% | -47.18% | -5.71% | -$977.3K |
Elite Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns ELTP or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of 58.86% compared to Elite Pharmaceuticals, Inc.'s net margin of 96.33%. Elite Pharmaceuticals, Inc.'s return on equity of 77.64% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital ELTPElite Pharmaceuticals, Inc.39.78% $0.01 $86.4M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About ELTP or ACAD?
Elite Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 922.5%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.80 which suggests that it could grow by 39.41%. Given that Elite Pharmaceuticals, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Elite Pharmaceuticals, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ELTPElite Pharmaceuticals, Inc.0 0 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is ELTP or ACAD More Risky?
Elite Pharmaceuticals, Inc. has a beta of 0.350, which suggesting that the stock is 65.003% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.872%.
-
Which is a Better Dividend Stock ELTP or ACAD?
Elite Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Elite Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ELTP or ACAD?
Elite Pharmaceuticals, Inc. quarterly revenues are $31.6M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Elite Pharmaceuticals, Inc.'s net income of $18.6M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Elite Pharmaceuticals, Inc.'s price-to-earnings ratio is 18.03x while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elite Pharmaceuticals, Inc. is 3.08x versus 3.61x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ELTPElite Pharmaceuticals, Inc.3.08x 18.03x $31.6M $18.6M ACADACADIA Pharmaceuticals, Inc.3.61x 9.97x $284M $273.6M
-
Which has Higher Returns ELTP or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of 58.86% compared to Elite Pharmaceuticals, Inc.'s net margin of 16.99%. Elite Pharmaceuticals, Inc.'s return on equity of 77.64% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital ELTPElite Pharmaceuticals, Inc.39.78% $0.01 $86.4M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About ELTP or ALNY?
Elite Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 922.5%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 40.59%. Given that Elite Pharmaceuticals, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Elite Pharmaceuticals, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ELTPElite Pharmaceuticals, Inc.0 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is ELTP or ALNY More Risky?
Elite Pharmaceuticals, Inc. has a beta of 0.350, which suggesting that the stock is 65.003% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.901%.
-
Which is a Better Dividend Stock ELTP or ALNY?
Elite Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Elite Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ELTP or ALNY?
Elite Pharmaceuticals, Inc. quarterly revenues are $31.6M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Elite Pharmaceuticals, Inc.'s net income of $18.6M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Elite Pharmaceuticals, Inc.'s price-to-earnings ratio is 18.03x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 144.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elite Pharmaceuticals, Inc. is 3.08x versus 11.68x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ELTPElite Pharmaceuticals, Inc.3.08x 18.03x $31.6M $18.6M ALNYAlnylam Pharmaceuticals, Inc.11.68x 144.02x $1.1B $186.4M
-
Which has Higher Returns ELTP or GKOS?
Glaukos Corp. has a net margin of 58.86% compared to Elite Pharmaceuticals, Inc.'s net margin of -93.39%. Elite Pharmaceuticals, Inc.'s return on equity of 77.64% beat Glaukos Corp.'s return on equity of -25.22%.
Company Gross Margin Earnings Per Share Invested Capital ELTPElite Pharmaceuticals, Inc.39.78% $0.01 $86.4M GKOSGlaukos Corp.77.8% -$2.32 $762.7M -
What do Analysts Say About ELTP or GKOS?
Elite Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 922.5%. On the other hand Glaukos Corp. has an analysts' consensus of $134.79 which suggests that it could grow by 11.28%. Given that Elite Pharmaceuticals, Inc. has higher upside potential than Glaukos Corp., analysts believe Elite Pharmaceuticals, Inc. is more attractive than Glaukos Corp..
Company Buy Ratings Hold Ratings Sell Ratings ELTPElite Pharmaceuticals, Inc.0 0 0 GKOSGlaukos Corp.10 0 1 -
Is ELTP or GKOS More Risky?
Elite Pharmaceuticals, Inc. has a beta of 0.350, which suggesting that the stock is 65.003% less volatile than S&P 500. In comparison Glaukos Corp. has a beta of 0.697, suggesting its less volatile than the S&P 500 by 30.259%.
-
Which is a Better Dividend Stock ELTP or GKOS?
Elite Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Glaukos Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Elite Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Glaukos Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ELTP or GKOS?
Elite Pharmaceuticals, Inc. quarterly revenues are $31.6M, which are smaller than Glaukos Corp. quarterly revenues of $143.1M. Elite Pharmaceuticals, Inc.'s net income of $18.6M is higher than Glaukos Corp.'s net income of -$133.7M. Notably, Elite Pharmaceuticals, Inc.'s price-to-earnings ratio is 18.03x while Glaukos Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elite Pharmaceuticals, Inc. is 3.08x versus 13.65x for Glaukos Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ELTPElite Pharmaceuticals, Inc.3.08x 18.03x $31.6M $18.6M GKOSGlaukos Corp.13.65x -- $143.1M -$133.7M
-
Which has Higher Returns ELTP or SVRA?
Savara, Inc. has a net margin of 58.86% compared to Elite Pharmaceuticals, Inc.'s net margin of --. Elite Pharmaceuticals, Inc.'s return on equity of 77.64% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital ELTPElite Pharmaceuticals, Inc.39.78% $0.01 $86.4M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About ELTP or SVRA?
Elite Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 922.5%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 79.91%. Given that Elite Pharmaceuticals, Inc. has higher upside potential than Savara, Inc., analysts believe Elite Pharmaceuticals, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ELTPElite Pharmaceuticals, Inc.0 0 0 SVRASavara, Inc.6 0 0 -
Is ELTP or SVRA More Risky?
Elite Pharmaceuticals, Inc. has a beta of 0.350, which suggesting that the stock is 65.003% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.311, suggesting its less volatile than the S&P 500 by 68.931%.
-
Which is a Better Dividend Stock ELTP or SVRA?
Elite Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Elite Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ELTP or SVRA?
Elite Pharmaceuticals, Inc. quarterly revenues are $31.6M, which are larger than Savara, Inc. quarterly revenues of --. Elite Pharmaceuticals, Inc.'s net income of $18.6M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Elite Pharmaceuticals, Inc.'s price-to-earnings ratio is 18.03x while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elite Pharmaceuticals, Inc. is 3.08x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ELTPElite Pharmaceuticals, Inc.3.08x 18.03x $31.6M $18.6M SVRASavara, Inc.-- -- -- -$29.6M
-
Which has Higher Returns ELTP or YCBD?
cbdMD, Inc. has a net margin of 58.86% compared to Elite Pharmaceuticals, Inc.'s net margin of -5.64%. Elite Pharmaceuticals, Inc.'s return on equity of 77.64% beat cbdMD, Inc.'s return on equity of -47.18%.
Company Gross Margin Earnings Per Share Invested Capital ELTPElite Pharmaceuticals, Inc.39.78% $0.01 $86.4M YCBDcbdMD, Inc.54.93% -$0.04 $9.6M -
What do Analysts Say About ELTP or YCBD?
Elite Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 922.5%. On the other hand cbdMD, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 146.31%. Given that Elite Pharmaceuticals, Inc. has higher upside potential than cbdMD, Inc., analysts believe Elite Pharmaceuticals, Inc. is more attractive than cbdMD, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ELTPElite Pharmaceuticals, Inc.0 0 0 YCBDcbdMD, Inc.0 0 0 -
Is ELTP or YCBD More Risky?
Elite Pharmaceuticals, Inc. has a beta of 0.350, which suggesting that the stock is 65.003% less volatile than S&P 500. In comparison cbdMD, Inc. has a beta of 2.127, suggesting its more volatile than the S&P 500 by 112.722%.
-
Which is a Better Dividend Stock ELTP or YCBD?
Elite Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. cbdMD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Elite Pharmaceuticals, Inc. pays -- of its earnings as a dividend. cbdMD, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ELTP or YCBD?
Elite Pharmaceuticals, Inc. quarterly revenues are $31.6M, which are larger than cbdMD, Inc. quarterly revenues of $5M. Elite Pharmaceuticals, Inc.'s net income of $18.6M is higher than cbdMD, Inc.'s net income of -$283.1K. Notably, Elite Pharmaceuticals, Inc.'s price-to-earnings ratio is 18.03x while cbdMD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elite Pharmaceuticals, Inc. is 3.08x versus 0.26x for cbdMD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ELTPElite Pharmaceuticals, Inc.3.08x 18.03x $31.6M $18.6M YCBDcbdMD, Inc.0.26x -- $5M -$283.1K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
50
AXTI alert for Mar 3
AXT, Inc. [AXTI] is down 9.65% over the past day.
Buy
53
AAOI alert for Mar 3
Applied Optoelectronics, Inc. [AAOI] is down 6.93% over the past day.
Sell
32
TPB alert for Mar 3
Turning Point Brands, Inc. [TPB] is down 0.87% over the past day.
